Guide to the correct way to take cabergoline, no more confusion when taking the medicine!

Cabergoline is a commonly used dopamine receptor agonist, widely used in the treatment of hyperprolactinemia (HPRL), especially for symptoms of excessive prolactin caused by pituitary adenomas, such as irregular menstruation, galactorrhea, etc. Correct dosing is the key to ensuring the efficacy of cabergoline and avoiding adverse reactions.

The standard starting dose of cabergoline is usually0.25 mg twice weekly. The lower starting dose helps evaluate patients' tolerance and treatment response, while reducing common side effects such as hypotension, dizziness, etc. After starting treatment, based on the patient's serum prolactin level, the doctor will adjust the dose as needed, usually increasing by 0.25mg every 4 weeks until reaching the maximum dose of 1mg twice a week. The interval between dose adjustments should be at least 4 weeks to avoid the impact of too rapid changes on patient health.

Cabergoline is an oral medication and should be taken after meals to reduce gastrointestinal irritation, especially side effects such as nausea. The oral administration of drugs should be strictly implemented in accordance with the doctor's instructions and avoid changing the dosage or frequency on your own to ensure the continuity and effect of treatment. When patients experience dizziness or hypotension, they should avoid standing too fast and gradually change their position to ensure the safety of medication.

For patients whose treatment period exceeds6 months, if the serum prolactin level has returned to the normal range and remains stable, doctors may consider gradually discontinuing the drug. However, patients need regular monitoring of prolactin levels after discontinuation of the drug. If serum prolactin levels rebound or symptoms return, treatment may need to be restarted. Therefore, regular follow-up and monitoring are important parts of cabergoline treatment that cannot be ignored.

In addition, although cabergoline is generally safe for patients, the therapeutic efficacy and safety of long-term use for more than 24 months have not yet been determined, so long-term treatment requires regular evaluation by a physician.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets